采用扩增阻滞突变系统聚合酶链反应（ARMS PCR）对一系列甲状腺乳头状癌及其配对淋巴结转移灶进行BRAF突变检测。
Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
作者信息
Zhang Jian, Yang Yaoyao, Zhao Jing, Shi Lifang, Xu Yanhua, Yu Kaikai, Guo Chongyong
机构信息
Department of Pathology, Binzhou People's Hospital, No. 515 Huanghe 7th Road, Binzhou, Shandong Province, 256600, PR China.
Department of Rehabilitation Training, Binzhou People's Hospital, No. 515 Huanghe 7th Road, Binzhou, Shandong Province, 256600, PR China.
出版信息
Pathol Res Pract. 2019 Apr;215(4):761-765. doi: 10.1016/j.prp.2019.01.006. Epub 2019 Jan 19.
OBJECTIVES
To figure out that if there is a consistency relationship of the BRAF mutation in matched-lymph node metastasis and original papillary thyroid carcinoma (PTC) specimen for the same patient.
METHODS
We collected the specimen of thyroids and matched-lymph node metastases of PTCs and tested the BRAF mutation status with amplification refractory mutation system (ARMS) PCR.
RESULTS
20 patients with PTC and metastasis lymph node were hired. In this cohort, 16 (80%) patients had the same BRAF genetic mutation status in thyroid and metastasis, and the other 4 (20%) had an inconsistent situation.
CONCLUSIONS
Within our cohort, the data suggested that wild-type BRAF oncogene in thyroid primary tumor does not rule out its mutation in lymph node metastasis, and vice versa.
目的
明确同一患者匹配的淋巴结转移灶与原发性甲状腺乳头状癌（PTC）标本中BRAF突变是否存在一致性关系。
方法
我们收集了PTC患者的甲状腺及匹配的淋巴结转移灶标本，采用扩增阻滞突变系统（ARMS）PCR检测BRAF突变状态。
结果
纳入20例PTC伴转移淋巴结患者。在该队列中，16例（80%）患者甲状腺和转移灶的BRAF基因突变状态相同，另外4例（20%）情况不一致。
结论
在我们的队列中，数据表明甲状腺原发性肿瘤中的野生型BRAF癌基因不能排除其在淋巴结转移灶中发生突变，反之亦然。
Zotero 插件